Cytosurge AG spins off its 3D printing business unit

Based on its patented FluidFM technology, Cytosurge AG develops, manufactures and distributes state-of-the-art nanotechnology and life sciences solutions, such as the versatile stand-alone FluidFM BOT system for single-cell research and FluidFM ADD-ONs for selected Atomic Force Microscopes (AFMs). Originally developed at ETH Zurich 10 years ago, FluidFM has already resulted in several highly innovative solutions for customers in the pharmaceutical industry as well as academic research in the field of cell- and bioscience.

The company’s team has shown an impressive pace and commitment to bring the FluidFM micro 3D printing technology to commercial readiness. This, together with a positive market response from academia and industries, such as semiconductor and watchmaking, laid the foundation for the strategic decision to spin-off the former Cytosurge 3D Printing business unit into an independent company under the name Exaddon.

Exaddon was initiated two-and-a-half-years ago via a strategic decision to explore the applicability of Cytosurge’s proprietary FluidFM technology to the field of additive micro-manufacturing of micro metal parts. Led by Edgar Hepp, Exaddon will focus entirely on providing solutions for processes and instruments of the stated field as well as serve existing and future Cytosurge 3D Printing clients. Exaddon’s core product is the “CERES” system, a 3D metal printing solution that prints with nanometer resolution tiny objects in sizes from 1 µm to up to 1000 µm. CERES is fully developed and ready for new challenges. The company will continue to

“Given the unique nature of the additive manufacturing business and specific requirements of our key target markets such as the semiconductor industry, we are convinced that an Exaddon can realize the high growth opportunities in this emerging market much better if it can focus entirely on this key goal. We are very proud to announce today the establishment of Exaddon AG for this purpose and I am convinced that Edgar and his team will thrive,” says Pascal Behr, CEO of Cytosurge.

Because of the technological proximity of the two companies, Exaddon and Cytosurge will continue to collaborate closely and cooperate on selected strategic projects together. At the same time, each entity now has a much clearer strategic focus which is expected to benefit both companies as well as their current and future clients.

(Press release)